Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
flowchart TD
events_adpd_2026_clinical_tria["AD/PD 2026 Clinical Trial Updates"]
events_adpd_2026_clinical_tria["Dates"]
events_adpd_2026_clinical_tria -->|"related to"| events_adpd_2026_clinical_tria
style events_adpd_2026_clinical_tria fill:#81c784,stroke:#333,color:#000
events_adpd_2026_clinical_tria["March"]
events_adpd_2026_clinical_tria -->|"related to"| events_adpd_2026_clinical_tria
style events_adpd_2026_clinical_tria fill:#81c784,stroke:#333,color:#000
events_adpd_2026_clinical_tria["Location"]
events_adpd_2026_clinical_tria -->|"related to"| events_adpd_2026_clinical_tria
style events_adpd_2026_clinical_tria fill:#81c784,stroke:#333,color:#000
events_adpd_2026_clinical_tria["Copenhagen"]
events_adpd_2026_clinical_tria -->|"related to"| events_adpd_2026_clinical_tria
style events_adpd_2026_clinical_tria fill:#81c784,stroke:#333,color:#000
style events_adpd_2026_clinical_tria fill:#4fc3f7,stroke:#333,color:#000
AD/PD 2026 featured significant clinical trial updates across both Alzheimer's disease and Parkinson's disease. This page summarizes the key trial results, regulatory developments, and pipeline advancements presented at the conference["@adpd2026"].
Alzheimer's Disease Clinical Trials
Anti-Amyloid Immunotherapies
Leqembi (Lecanemab) - Eisai/Biogen The CLARITY-AD trial continue to demonstrate sustained benefits:
... Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
Mermaid diagram (expand to render)
AD/PD 2026 featured significant clinical trial updates across both Alzheimer's disease and Parkinson's disease. This page summarizes the key trial results, regulatory developments, and pipeline advancements presented at the conference["@adpd2026"].
Alzheimer's Disease Clinical Trials
Anti-Amyloid Immunotherapies
Leqembi (Lecanemab) - Eisai/Biogen The CLARITY-AD trial continue to demonstrate sustained benefits:
Phase 3 Extension Data: 36-month follow-up showing maintained cognitive benefitsReal-World Evidence: Post-approval data supporting clinical effectivenessSafety Profile: Updated ARIA monitoring protocols based on real-world useCombination Approaches: Trials combining lecanemab with other modalitiesDonanemab - Eli Lilly The TRAILBLAZER-ALZ 2 trial results continue to evolve:
Population Expansion: Results in broader patient populationsBiomarker Correlations: Amyloid plaque reduction correlates with clinical outcomesSafety Updates: Managing ARIA incidence in clinical practiceSequencing Strategies: Planning for treatment-naive vs. prior treatment patientsGantenerumab - Roche/Genentech Development program updates:
SCarlet RoAD and Marguerite RoAD: Long-term follow-up dataNext-Generation Approaches: Reformulated delivery methods under investigationAnti-Tau Therapies
Tau Immunotherapy Programs Multiple anti-tau antibodies advancing through clinical development:
LMTM (Tau Aggregation Inhibitor) - TauRx: Phase 3 results and regulatory discussionsSemorinemab - Roche: Phase 2 safety and efficacy dataJNJ-63733657 - Janssen: First-in-human study resultsAPNmAb05 - AbbVie: Early-stage trial updatesTau PET Tracer Development Imaging biomarkers for tau pathology:
PI-2620 - AC Immune/Roche: Cross-validation with neuropathologyAPN-1607 - Aprinoia: Broader applicability in AD spectrumNeuroinflammation Targets
TREM2 Modulation Genetic and pharmacologic approaches targeting microglial dysfunction:
AL002 - Alector/AbbVie: TREM2 agonist clinical developmentAL003 - Alector: Anti-TREM2 antibody programsComplement Inhibition Complement pathway as therapeutic target:
Eculizumab - Alexion: Complement inhibition in neurodegenerative diseasesAPD001 - Apogee: Novel complement modulatorsDisease Modification Approaches
Synaptic Protection
Bryostatin - Neurotrope: PKC modulators for synaptic functionLucerstat - Cerenis: HDL mimetics for amyloid clearanceT3D-959 - T3D Therapeutics: PPAR delta/gamma agonistPioglitazone - Takeda: Repurposing for ADParkinson's Disease Clinical Trials
Alpha-Synuclein-Targeted Therapies
Immunotherapies Active and passive immunization approaches:
PRX002 (Pasinersen) - Prothelia/Roche: Anti-alpha-synuclein antisenseABBV-951 - AbbVie: Subcutaneous alpha-synuclein antibodyUCB0599 - UCB: Small molecule alpha-synuclein modulatorAggregation Inhibitors Small molecule approaches:
Anle138b - MODAG: Alpha-synuclein oligomer modulatorPD01A -AFFiRiS: Active immunization candidateLRRK2 Inhibitors
DNL151 - Denali/Lilly LRRK2 inhibitor program updates:
Phase 1b Results: Target engagement and safety dataPhase 2 Planning: Dose selection for efficacy studiesBiomarker Development: pS935-LRRK2 as pharmacodynamic markerBIIB122 (DNL311) - Denali/Biogen LRRK2 inhibitor collaboration:
Clinical Development: Advancement through clinical phasesGenetic Subgroup Analysis: Response in LRRK2 mutation carriersGene Therapy Approaches
AAV-Based Delivery
AAV2-GAD - Neurologix: Glutamic acid decarboxylase gene therapyAAV-AADC - Voyager Therapeutics: Aromatic L-amino acid decarboxylaseVY-AADC02 - Voyager: Optimized gene delivery for PDGene Silencing
ASOs for GBA - Ionis: Targeting glucocerebrosidase mutationsSNCA Targeting - UniQure: siRNA approaches for alpha-synuclein reductionMotor Complications
Levodopa-Induced Dyskinesias Managing motor complications:
Levodopa-Carbidopa Intestinal Gel (LCIG) - AbbVie: Long-term outcomesND0612 - Neuroderm: Continuous subcutaneous levodopa deliveryABBV-951 - AbbVie: Subcutaneous levodopa/carbidopa pumpDisease Modification
Inosine - Michael J. Fox Foundation: Urate elevation for neuroprotectionGDNF - Virin: Glial cell line-derived neurotrophic factorNeuroprotective Strategies
CoQ10 - Various: Mitochondrial protection approachesIsradipine - NINDS: Calcium channel blockadeCreatine - NINDS: Energy metabolism supportBiomarker-Driven Trials
Blood-Based Biomarkers in Clinical Trials Integration of fluid biomarkers for patient selection and monitoring:
p-Tau217 - Lilly: Regulatory qualification for trial enrichmentp-Tau181 - Roche: Cross-platform standardizationNfL - Various: Neurodegeneration monitoringα-Synuclein SAA - Various: Seed amplification for PD diagnosisPrecision Medicine Approaches Genetic stratification in clinical trials:
GBA Carriers: Specialized trial cohorts for Gaucher disease-associated PDLRRK2 Carriers: Targeted enrollment for LRRK2 inhibitor trialsSNCA Multiplication: Rare genetic subtype studiesRegulatory and Development News
FDA Updates
Accelerated Approval Pathway: Lessons from recent AD approvalsBiomarker Qualification: Regulatory pathways for novel biomarkersCombination Therapy Guidance: Framework for multi-target approachesEMA Perspectives
Adaptive Trial Designs: Flexibility in late-stage developmentReal-World Evidence: Post-approval requirements evolutionTrial Design Innovations
Master Protocols
Platform Trials: Adaptive designs for multiple interventionsBasket Trials: histology-agnostic approaches based on biomarkersEnrichment Strategies
Biomarker-Positive Selection: Recruiting patients with evidence of target engagementGenetic Pre-Screening: Identifying eligible populations earlyRemote and Hybrid Trials
Decentralized Elements: Remote monitoring and virtual visitsDigital Endpoints: Digital biomarker integrationFuture Trial Outlook
Upcoming readouts (2026-2027)
Multiple anti-amyloid Phase 3 results expected
LRRK2 inhibitor Phase 2 data anticipated
Alpha-synuclein immunotherapy results
Pipeline Health
Over 150 compounds in active clinical development for AD
Over 80 compounds in active clinical development for PD
Increasing focus on combination approaches
See Also
[AD/PD 2026 Conference](/events/adpd-2026)](/events)
[AD/PD 2026 Scientific Sessions](/events/adpd-2026-scientific-sessions)](/events)
[AD/PD 2026 Emerging Therapeutic Targets](/events/adpd-2026-emerging-therapeutic-targets)](/events)
[AD/PD 2026 Company Presentations](/events/adpd-2026-company-presentations)](/events)
[AD/PD 2026 Plenary Sessions](/events/adpd-2026-plenary-sessions)](/events)
[Clinical Trials Index](/content/clinical-trials)
References
Unknown, AD/PD 2026 Conference Website (2026)
[Cummings J, et al., Alzheimer's & Dementia. 2024 (2024)](/[DOI:10.1002/alz.13811](https://doi.org/10.1002/alz.13811))
[Foltynie T, et al., J Parkinsons Dis. 2024 (2024)](/[DOI:10.3233/JPD-249001](https://doi.org/10.3233/JPD-249001)) Show full description